Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT J BUYNAK

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1508977984
CMS profile
340544
Location
VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$5,627.38

35 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $3,839.80 17
Food and Beverage $1,787.58 18

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk AS $2,690.52 10
EISAI INC. $1,725.98 16
Amgen Inc. $1,114.52 8
Gilead Sciences, Inc. $96.36 1

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT J BUYNAK

NPI 1508977984 · CMS profile ID 340544

Allopathic & Osteopathic Physicians / Internal Medicine

VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508977984?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508977984?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508977984?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1508977984?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

35 matching records · $5,627.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 35 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–35 of 35.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk AS $337.3512/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542047 CMS
Novo Nordisk AS $193.5512/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542049 CMS
Novo Nordisk AS $80.5312/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542051 CMS
Novo Nordisk AS $149.6012/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542053 CMS
Novo Nordisk AS $274.8312/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543971 CMS
Gilead Sciences, Inc. $96.3611/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681487429 CMS
EISAI INC. $123.8106/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697037999 CMS
EISAI INC. $40.1806/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697038001 CMS
EISAI INC. $405.1206/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048429 CMS
EISAI INC. $343.8006/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048431 CMS
EISAI INC. $225.0006/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048433 CMS
EISAI INC. $57.3506/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048511 CMS
EISAI INC. $87.0006/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048513 CMS
EISAI INC. $130.0006/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048515 CMS
EISAI INC. $71.3106/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048517 CMS
EISAI INC. $38.7306/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048519 CMS
EISAI INC. $22.5106/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048521 CMS
EISAI INC. $46.8306/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048523 CMS
EISAI INC. $23.4106/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048525 CMS
EISAI INC. $45.8006/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048527 CMS
EISAI INC. $23.3506/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048529 CMS
EISAI INC. $41.7806/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048531 CMS
Novo Nordisk AS $224.8705/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542041 CMS
Novo Nordisk AS $328.4805/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542043 CMS
Novo Nordisk AS $301.3105/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542045 CMS
Novo Nordisk AS $400.0005/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543967 CMS
Novo Nordisk AS $400.0005/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543969 CMS
Amgen Inc. $46.2301/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663344227 CMS
Amgen Inc. $23.1101/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663344231 CMS
Amgen Inc. $46.2301/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663344233 CMS
Amgen Inc. $23.1101/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663344235 CMS
Amgen Inc. $385.3601/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663344217 CMS
Amgen Inc. $123.8801/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663344221 CMS
Amgen Inc. $304.2001/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663344225 CMS
Amgen Inc. $162.4001/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663344239 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,627.38 35
PY2022 $1,515.77 9
PY2023 $2,547.31 21
PY2024 $2,804.68 27
PY2025 $2,542.53 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,038,550.53 603
PY2024 Principal investigator $5,031,915.33 601
PY2023 Recipient $906.71 2
PY2023 Principal investigator $4,138,599.32 2,384
PY2022 Recipient $3,104.59 10
PY2022 Principal investigator $5,204,363.35 1,133
PY2021 Principal investigator $3,348,948.64 610
PY2020 Recipient $1,489.26 13
PY2020 Principal investigator $1,938,354.41 292
PY2019 Recipient $658.79 10
PY2019 Principal investigator $1,439,149.33 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

305 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,689.33 12/31/2020 Non-covered Recipient Entity
Buynak Clinical Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 736738531
Principal investigator 1 SANOFI PASTEUR INC. $62,850.00 12/29/2020 Non-covered Recipient Entity
Velocity Clinical Research,Inc
PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years No dispute reported 06/30/2026 744043575
Principal investigator 1 Novo Nordisk AS $41.00 12/28/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 822166403
Principal investigator 1 Gilead Sciences, Inc. $1,411.00 12/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 742089353
Principal investigator 1 Janssen Research & Development, LLC $913,523.00 12/22/2020 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719530273
Principal investigator 1 Novo Nordisk AS $358.56 12/22/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380059
Principal investigator 1 Novo Nordisk AS $3,896.46 12/22/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380063
Principal investigator 1 Novo Nordisk AS $45.00 12/21/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 822166405
Principal investigator 1 Kowa Research Institute, Inc. $1,769.40 12/18/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664277
Principal investigator 1 Novo Nordisk AS $72.00 12/18/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 822171817
Principal investigator 1 PFIZER INC. $1,495.00 12/18/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 742896413
Principal investigator 1 Janssen Research & Development, LLC $5,997.00 12/17/2020 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719530271
Principal investigator 1 PFIZER INC. $10,500.00 12/17/2020 Non-covered Recipient Entity
Velocity Clinical Research Inc
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 742896411
Principal investigator 1 PFIZER INC. $110.89 12/08/2020 Non-covered Recipient Entity
Buynak Clinical Research
A 16WEEK PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN No dispute reported 06/30/2026 742900123
Principal investigator 1 SANOFI PASTEUR INC. $1,925.00 12/08/2020 Non-covered Recipient Entity
Velocity Clinical Research,Inc
PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years No dispute reported 06/30/2026 744043535
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 12/03/2020 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719530269
Principal investigator 1 Novo Nordisk AS $41.00 12/02/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 822166399
Principal investigator 1 Novo Nordisk AS $41.00 12/01/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 822166401
Principal investigator 1 Novo Nordisk AS $6,514.35 11/30/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380061
Principal investigator 1 Janssen Research & Development, LLC $184,653.00 11/24/2020 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719530267
Principal investigator 1 Novo Nordisk AS $1,456.92 11/24/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380057
Principal investigator 1 Novo Nordisk AS $41.06 11/20/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380041
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,900.00 11/17/2020 Non-covered Recipient Entity
Velocity Clinical Research
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 736736205
Principal investigator 1 Kowa Research Institute, Inc. $3,002.40 11/03/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664273
Principal investigator 1 Novo Nordisk AS $12,550.01 10/29/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380047
Principal investigator 1 Novo Nordisk AS $4,102.92 10/29/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380053
Principal investigator 1 Novo Nordisk AS $36.00 10/26/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380037
Principal investigator 1 Janssen Research & Development, LLC $22,320.00 10/15/2020 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719530265
Principal investigator 1 Janssen Research & Development, LLC $100,000.00 10/14/2020 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants No dispute reported 06/30/2026 719530263
Principal investigator 1 Eisai Inc. $23.00 10/06/2020 Non-covered Recipient Entity
Buynak Clinical Research PC
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 749109193
Principal investigator 1 Eisai Inc. $16,082.20 10/06/2020 Non-covered Recipient Entity
Buynak Clinical Research PC
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 749109229
Principal investigator 1 Kowa Research Institute, Inc. $4,932.90 10/01/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664267
Principal investigator 1 Novo Nordisk AS $23.06 09/25/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380055
Principal investigator 1 Novo Nordisk AS $8,539.92 09/24/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380045
Principal investigator 1 SANOFI PASTEUR INC. $8,000.00 09/24/2020 Non-covered Recipient Entity
Velocity Clinical Research,Inc
PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years No dispute reported 06/30/2026 744043461
Principal investigator 1 Gilead Sciences, Inc. $879.00 09/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 742089351
Principal investigator 1 Novo Nordisk AS $739.80 09/22/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380051
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $30,018.00 09/01/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EFC-14875 No dispute reported 06/30/2026 752054301
Principal investigator 1 Novo Nordisk AS $24.99 08/27/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380029
Principal investigator 1 Novo Nordisk AS $7,491.42 08/27/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380043
Principal investigator 1 Kowa Research Institute, Inc. $2,783.70 08/26/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664257
Principal investigator 1 Novo Nordisk AS $1,838.16 08/25/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380049
Principal investigator 1 Novo Nordisk AS $24.99 08/21/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380035
Principal investigator 1 PFIZER INC. $34.38 08/20/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742922269
Principal investigator 1 Eisai Inc. $15,631.00 08/19/2020 Non-covered Recipient Entity
Buynak Clinical Research PC
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 749109219
Principal investigator 1 Novo Nordisk AS $27.96 08/19/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380033
Principal investigator 1 Novo Nordisk AS $27.96 08/14/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380031
Principal investigator 1 Novo Nordisk AS $10,203.81 07/30/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379849
Principal investigator 1 Novo Nordisk AS $358.56 07/28/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379845
Principal investigator 1 Kowa Research Institute, Inc. $3,003.30 07/27/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664261
Principal investigator 1 Novo Nordisk AS $27.96 07/24/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380039
Principal investigator 1 Amgen Inc. $1,350.00 07/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH P C
GALACTIC - HF No dispute reported 06/30/2026 731630787
Principal investigator 1 Gilead Sciences, Inc. $65.00 07/22/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 742089349
Principal investigator 1 Novo Nordisk AS $24.99 06/26/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379851
Principal investigator 1 Novo Nordisk AS $46.36 06/26/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379853
Principal investigator 1 Kowa Research Institute, Inc. $3,464.10 06/25/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664245
Principal investigator 1 Novo Nordisk AS $358.56 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379843
Principal investigator 1 Novo Nordisk AS $14,475.45 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379847
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379855
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379857
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379859
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379861
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379863
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379865
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379867
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379869
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379871
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379873
Principal investigator 1 Novo Nordisk AS $24.95 06/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379875
Principal investigator 1 PFIZER INC. $653.32 06/18/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742955239
Principal investigator 1 Gilead Sciences, Inc. $1,073.00 06/17/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 742089347
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379877
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379879
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379881
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379883
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379885
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379887
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379889
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379891
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379893
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379895
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379897
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379899
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379901
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379903
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379905
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379907
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379909
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379911
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379913
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379915
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379917
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379919
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379921
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379923
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379925
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379927
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379929
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379931
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379933
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379935
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379937
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379939
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379941
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379943
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379945
Principal investigator 1 Novo Nordisk AS $12.75 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379947
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379949
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379951
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379953
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379955
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379957
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379959
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379961
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379963
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379965
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379967
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379969
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379971
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379973
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379975
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379977
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379979
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379981
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379983
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379985
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379987
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379989
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379991
Principal investigator 1 Novo Nordisk AS $56.90 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379993
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380015
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380017
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380019
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380021
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380023
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380025
Principal investigator 1 Novo Nordisk AS $16.25 06/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742380027
Principal investigator 1 Novo Nordisk AS $4.90 06/11/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380009
Principal investigator 1 Novo Nordisk AS $36.00 06/11/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380011
Principal investigator 1 Novo Nordisk AS $5.30 06/09/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379995
Principal investigator 1 Novo Nordisk AS $49.98 06/09/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379997
Principal investigator 1 Novo Nordisk AS $9.00 06/09/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379999
Principal investigator 1 Novo Nordisk AS $60.00 06/09/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380001
Principal investigator 1 Novo Nordisk AS $6.50 06/09/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380003
Principal investigator 1 Novo Nordisk AS $9.00 06/09/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380005
Principal investigator 1 Novo Nordisk AS $36.00 06/09/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380007
Principal investigator 1 Novo Nordisk AS $23.46 06/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742380013
Principal investigator 1 Kowa Research Institute, Inc. $2,584.80 06/01/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664251
Principal investigator 1 Novo Nordisk AS $12,133.19 05/28/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379619
Principal investigator 1 Novo Nordisk AS $1,203.12 05/28/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379621
Principal investigator 1 Novo Nordisk AS $23.46 05/27/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379839
Principal investigator 1 PFIZER INC. $4,117.94 05/21/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742955255
Principal investigator 1 Novo Nordisk AS $74.97 05/15/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379841
Principal investigator 1 Kowa Research Institute, Inc. $1,358.10 05/12/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664241
Principal investigator 1 Kowa Research Institute, Inc. $1,896.30 05/01/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664235
Principal investigator 1 Novo Nordisk AS $31,737.53 04/30/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379617
Principal investigator 1 Novo Nordisk AS $75.00 04/28/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379717
Principal investigator 1 Novo Nordisk AS $75.00 04/28/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379719
Principal investigator 1 Gilead Sciences, Inc. $2,367.00 04/27/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 742089345
Principal investigator 1 Novo Nordisk AS $3,000.00 04/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379613
Principal investigator 1 Novo Nordisk AS $1,270.00 04/23/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379615
Principal investigator 1 Eisai Inc. $16,196.40 04/22/2020 Non-covered Recipient Entity
Buynak Clinical Research PC
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 749109171
Principal investigator 1 Novo Nordisk AS $49.98 04/17/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379721
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379667
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379669
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379671
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379673
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379675
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379677
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379679
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379681
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379683
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379685
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379687
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379689
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379691
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379693
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379695
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379697
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379699
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379701
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379703
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379705
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379707
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379709
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379711
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379713
Principal investigator 1 Novo Nordisk AS $16.25 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379715
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379723
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379725
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379727
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379729
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379731
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379733
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379735
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379737
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379739
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379741
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379743
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379745
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379747
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379749
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379751
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379753
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379755
Principal investigator 1 Novo Nordisk AS $25.50 04/07/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379757
Principal investigator 1 GlaxoSmithKline, LLC. $6,150.00 04/01/2020 Non-covered Recipient Entity
PHARMASEEK LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734918047
Principal investigator 1 Kowa Research Institute, Inc. $1,663.20 04/01/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664229
Principal investigator 1 Novo Nordisk AS $23.06 03/27/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379665
Principal investigator 1 Novo Nordisk AS $972.00 03/26/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379629
Principal investigator 1 PFIZER INC. $1,000.00 03/26/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742969059
Principal investigator 1 Eisai Inc. $20,883.60 03/23/2020 Non-covered Recipient Entity
Buynak Clinical Research PC
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 749109143
Principal investigator 1 Amgen Inc. $582.00 03/21/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
GALACTIC - HF No dispute reported 06/30/2026 731630775
Principal investigator 1 Gilead Sciences, Inc. $2,143.00 03/18/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 742089343
Principal investigator 1 Kowa Research Institute, Inc. $29,368.80 03/18/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664225
Principal investigator 1 Novo Nordisk AS $49.98 03/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379663
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379633
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379635
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379637
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379639
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379641
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379643
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379645
Principal investigator 1 Novo Nordisk AS $1.08 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379647
Principal investigator 1 Novo Nordisk AS $2.65 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379649
Principal investigator 1 Novo Nordisk AS $24.99 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379651
Principal investigator 1 Novo Nordisk AS $4.50 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379653
Principal investigator 1 Novo Nordisk AS $30.00 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379655
Principal investigator 1 Novo Nordisk AS $3.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379657
Principal investigator 1 Novo Nordisk AS $4.50 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379659
Principal investigator 1 Novo Nordisk AS $18.00 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379661
Principal investigator 1 Novo Nordisk AS $16.35 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379759
Principal investigator 1 Novo Nordisk AS $9.09 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379761
Principal investigator 1 Novo Nordisk AS $23.97 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379763
Principal investigator 1 Novo Nordisk AS $108.00 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379765
Principal investigator 1 Novo Nordisk AS $8.97 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379767
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379769
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379771
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379773
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379775
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379777
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379779
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379781
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379783
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379785
Principal investigator 1 Novo Nordisk AS $16.25 03/05/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379787
Principal investigator 1 Eisai Inc. $6,668.10 02/25/2020 Non-covered Recipient Entity
Buynak Clinical Research PC
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 749109173
Principal investigator 1 Novo Nordisk AS $1,458.00 02/25/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379625
Principal investigator 1 Novo Nordisk AS $16,320.00 02/25/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379627
Principal investigator 1 Gilead Sciences, Inc. $1,397.00 02/24/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 742089341
Principal investigator 1 Kowa Research Institute, Inc. $22,462.20 02/19/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664219
Principal investigator 1 Novo Nordisk AS $23.06 02/19/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379631
Principal investigator 1 PFIZER INC. $8,395.53 02/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742968997
Principal investigator 1 Amgen Inc. $1,178.91 01/29/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
GALACTIC - HF No dispute reported 06/30/2026 731630779
Principal investigator 1 Novo Nordisk AS $432.00 01/28/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379623
Principal investigator 1 Gilead Sciences, Inc. $2,717.00 01/27/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 742089339
Principal investigator 1 Kowa Research Institute, Inc. $9,837.00 01/24/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 721664213
Principal investigator 1 Novo Nordisk AS $23.06 01/24/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379837
Recipient GlaxoSmithKline, LLC. $69.58 01/22/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734914629
Recipient GlaxoSmithKline, LLC. $10.00 01/22/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734916671
Principal investigator 1 Eisai Inc. $15,447.60 01/21/2020 Non-covered Recipient Entity
Buynak Clinical Research PC
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 749109159
Principal investigator 1 SANOFI US SERVICES INC. $4,406.00 01/21/2020 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu No dispute reported 06/30/2026 744045373
Principal investigator 1 SANOFI US SERVICES INC. $295.00 01/21/2020 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu No dispute reported 06/30/2026 744078867
Principal investigator 1 Eisai Inc. $5,000.00 01/20/2020 Non-covered Recipient Entity
Buynak Clinical Research PC
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 749109141
Principal investigator 1 Novo Nordisk AS $24.99 01/16/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379789
Principal investigator 1 Romark Laboratories, LC $100,000.00 01/16/2020 Non-covered Recipient Entity
PharmaSeek
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection No dispute reported 06/30/2026 750774605
Principal investigator 1 SANOFI US SERVICES INC. $9,828.00 01/13/2020 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu No dispute reported 06/30/2026 744045411
Principal investigator 1 Amgen Inc. $43.81 01/09/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
GALACTIC - HF No dispute reported 06/30/2026 731630783
Principal investigator 1 Novo Nordisk AS $9.00 01/08/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379815
Principal investigator 1 Novo Nordisk AS $72.00 01/08/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 742379817
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,514.03 01/07/2020 Non-covered Recipient Entity
Buynak Clinical Research
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) No dispute reported 06/30/2026 736739895
Recipient GlaxoSmithKline, LLC. $349.60 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734899773
Recipient GlaxoSmithKline, LLC. $167.89 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734903649
Recipient GlaxoSmithKline, LLC. $85.27 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734905119
Recipient GlaxoSmithKline, LLC. $72.66 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734905973
Recipient GlaxoSmithKline, LLC. $36.54 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734906405
Recipient GlaxoSmithKline, LLC. $30.74 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734913615
Recipient GlaxoSmithKline, LLC. $24.23 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734913963
Recipient GlaxoSmithKline, LLC. $377.06 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734916309
Recipient GlaxoSmithKline, LLC. $202.68 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734928321
Recipient GlaxoSmithKline, LLC. $32.79 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734928323
Recipient GlaxoSmithKline, LLC. $30.22 01/07/2020 Covered Recipient Physician A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 734928401
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379791
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379793
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379795
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379797
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379799
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379801
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379803
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379805
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379807
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379809
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379811
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379813
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379819
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379821
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379823
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379825
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379827
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379829
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379831
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379833
Principal investigator 1 Novo Nordisk AS $28.45 01/06/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 742379835
Principal investigator 1 AstraZeneca Pharmaceuticals LP $48,442.80 01/02/2020 Non-covered Recipient Entity
Buynak Clinical Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 736749297
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,292.40 01/02/2020 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 965470793